Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential

Cellular Immunology

Volumn 265, Issue 1, 2010, Pages 23-30

  Liepert, Anja ^a   Grabrucker, Christine ^a   Kremser, Andreas ^a   Dreyßig, Julia ^a   Ansprenger, Christian ^a   Freudenreich, Markus ^a   Kroell, Tanja ^a   Reibke, Roland ^a   Tischer, Johanna ^a   Schweiger, Cornelia ^c   Schmid, Christoph ^b   Kolb, Hans Jochem ^a,d   Schmetzer, Helga ^a,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Municipal Hospital   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Acute myeloid leukemia; Dendritic cells; Immunotherapy; Serum free culture; Stem cell transplantation; T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR7;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL CULTURE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; ADAPTIVE IMMUNITY; ADOLESCENT; CYTOLOGY; CYTOTOXICITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MIXED LYMPHOCYTE CULTURE; PATHOLOGY; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; AGED; CHILD; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES; YOUNG ADULT;

EID: 77956173577     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.06.009     Document Type: Article

References (34)

1. Giles F.J., Keating A., Goldstone A.H., Avivi I., Willman C.L., Kantarjian H.M. Acute myeloid leukemia. Hematology 2002, 1:73-110.
2. Buechner T., Hiddemann W., Berdel W.E., Wörmann B., Schoch C., Fonatsch C., Löffler H., Haferlach T., Ludwig W.D., Maschmeyer G., Staib P., Aul C., Gruneisen A., Lengfelder E., Frickhofen N., Kern W., Serve H.L., Mesters R.M., Sauerland M.C., Heinecke A. 6-Thioguanine, cytarabine and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J. Clin. Oncol. 2003, 21:4496-4504.
3. Kolb H.-J., Schmid C., Barrett A., Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103:767-776.
4. Kolb H.J., Mittermüller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
5. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., van Rhee F., Mittermueller J., de Witte T., Holler E., Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfustions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood 1995, 86:2041-2050.
6. Schmid C., Schleuning M., Schwerdtfeger R., Hertenstein B., Mischak-Weissinger E., Bunjes D. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006, 108(3):1092-1099.
7. Campana D., Behm F.G. Immunophenotyping of leukemia. J. Immunol. Methods 2000, 243:59-75.
8. Restifo N.P., Minev B.R., Taggarse A.S., et al. Enhancing the recognition of tumor associated antigens. Folia Biol. (Praha) 1993, 40:74-88.
9. Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus. Apher. Sci. 2002, 27:183-186.
10. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 1997, 9:10-16.
11. Nestle F.O., Banchereau J., Hart D. Dendritic cells: on the move from the bench to bedside. Nat. Med. 2001, 7:761-765.
12. Claxton D.F., McMannis J., Champlin R., Choudhury A. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit. Rev. Immunol. 2001, 21:147-155.
13. Stripecke R., Levine A.M., Pullarkat V., Cardoso A.A. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 2002, 16:1974-1983.
14. J. Dreyßig, A. Kremser, S. Kufner, T. Kroell, R. Pelka-Fleischer, H. Zitzelsberger, F. delValle, C. Schweiger, H.l. Schmetzer, Expression profiles of Leukemia-derived dendritic cells in AML and MDS depending on different culture conditions, J. Cancer Mol. (2010), accepted for publication.
15. Kremser A., Dreyßig J., Grabrucker C., Liepert A., Kroell T., Scholl N., Schmid C., Tischer J., Kufner S., Salih H., Kolb H.J., Schmetzer H.M. Dendritic cells can be successfully generated from leukaemic blasts in individual patients with AML or MDS: an evaluation of different methods. J. Immunother. 2010, 33(2):185-199.
16. Schmetzer H. Dendritic cells as Prognostic Indicators or as Immunotherapeutic Tools to Treat Acute Myeloid Leukemia (AML) and High Grade Myelodysplasia (MDS). Review. Recent Adv. Res. Updates 2008, 9(1):125-137. (invited publication, award as eminent scientist of the year 2007).
17. Grabrucker C., Liepert A., Dreyßig J., Kremser A., Kroell T., Freudenreich M., Schmid C., Schweiger C., Tischer J., Kolb H.J., Schmetzer H.M. The quality and quantity of leukemia-derived dendritic cells (DC) from patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are a predictive factor for the lytic potential of DC-primed leukemia-specific T-cells. J. Immunother. 2010, 33(5):523-537.
18. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukaemias. Frenche-American-Brithish (FAB) co-operative group. Br. J. Haematol. 1976, 33:451-458.
19. Schmetzer H.M., Kremser A., Loibl J., Kroell T., Kolb H.J. Quantification of ex vivo generated dendritic cells (DC) and leukemia derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation procedures ex vivo or in vivo. Leukemia 2007, 21(6):1338-1341.
20. Kufner S., Fleischer R.P., Kroell T., Schmid C., Zitzelsberger H., Salih H., de Valle F., Treder W., Schmetzer H.M. Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol. Immunother. 2005, 54:953-970.
21. Lanzavecchia A., Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2002, 23:592-595.
22. Nguyen X.D., Eichler H., Dugrillon A., Piechaczek C., Braun M., Klüter H. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J. Immunol. Methods 2003, 9281:1-12.
23. Kienzle N., Olver S., Buttigieg K., Kelso A. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. J. Immunol. Methods 2002, 267:99-108.
24. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997, 90(9):3245-3287.
25. Cools N., Van Tendeloo V.F., Smits E.L., Lenjou M., Nijs G., Van Bockstaele D.R., Berneman Z.N., Ponsaerts P. Immunosuppression induced by immature dendritic cells is mediated by TGF-β/IL-10 double-positive CD4+ regulatory T-cells. J. Cell. Mol. Med. 2008, 12(2):690-700.
26. Lee S.H., Prince J.E., Rais M., Kheradmand F., Ballantyne C.M., Weitz-Schmidt G., Smith C.W., Corry D.B. Developmental control of integrin expression regulates Th2 effector homing. J. Immunol. 2008, 180(7):4656-4667.
27. Becker C., Stoll S., Bopp T., Schmitt E., Jonueit H. Regulatory T-cells: present facts and future hopes. Med. Microbiol. Immunol. 2006, 195(3):113-124.
28. Driessens G., Gordower L., Nuttin L., Stordeur P., Blocklet D., Egrise D., Velu T., Bruyns C. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T-cell recruitment and low relative regulatory T-cell infiltration. Cancer Immunol. Immunother. 2008, 57(12):1745-1756.
29. Falkenburg H.J., Wafelman A.R., Joosten P., Smit W.M., van Bergen C.A., Bongaerts R. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999, 94(4):1201-1208.
30. Giralt S., Hester J., Huh Y., Hirsch-Ginsberg C., Rondón G., Seong D. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995, 86(11):4337-4343.
31. Jedema I., Meji P., Steeneveld E., Hoogendoorn M., Nijmeijer B.A., van de Meent M. Early detection and rapid isolation of leukemia-reactive donor T-cells for adoptive transfer using the IFN-gamma secretion assay. Clin. Cancer Res. 2007, 13(2 Pt 1):636-643.
32. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T-cell subsets: function, generation and maintenance. Annu. Rev. Immunol. 2004, 22:745-763.
33. Klebanoff C.A., Gattinoni L., Restifo N.P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 2006, 211:214-224.
34. Schuster F., Buhmann R., Reuther S., Hubner B., Grabrucker C., Liepert A., Reibke R., Lichtner P., Yang T., Kroell T., Kolb H.J., Borkhardt A., Schmetzer H.M. Improved effector functions of leukaemia-specific T-lymphocyte clones primed with AML-derived dendritic cells. Cancer Genomic. Proteomic. 2008, 5:275-286.